Volition(US:VNRX)2025-10-08 16:02Summary of the Webinar on Epigenetic Modifications for Biomarker and Drug Discovery Industry and Company Involved - Industry: Biotechnology focusing on epigenetic modifications and cancer diagnostics - Companies: Volition and HelioGenomics Core Points and Arguments 1. Overview of Volition: Volition is a multinational company with R&D labs in Belgium and the U.S., aiming to save lives through innovative diagnostic technologies [2][3] 2. Nucleosomes and Epigenetic Modifications: Nucleosomes, composed of DNA and histone proteins, undergo various post-translational modifications (PTMs) that regulate gene expression and are implicated in diseases like cancer [3][4] 3. Nuclear Assays: Volition's nuclear assays quantitatively measure circulating nucleosomes and their modifications, with a portfolio of 14 assays targeting specific epigenetic features [4][5] 4. Diagnostic Potential: H3K27 trimethylation levels were significantly elevated in non-small cell lung cancer (NSCLC) patients, showing a 3.7 to 2.9-fold increase compared to healthy controls, indicating its potential as a diagnostic biomarker [11][12] 5. Prognostic Value: Elevated levels of H3K27 trimethyl nucleosomes were associated with worse outcomes in NSCLC, with a hazard ratio of 3.56, suggesting its use as a prognostic biomarker [41] 6. Combination with ctDNA: Combining H3K27 trimethyl status with circulating tumor DNA (ctDNA) improved patient identification by 15.1%, enhancing the sensitivity of blood-based assays [13][50] 7. EZH2 Inhibitors: EZH2 inhibitors, such as ORIC-944, show promise in treating cancers by targeting the PRC2 complex, with ongoing clinical trials demonstrating their efficacy [16][17] 8. Immunogenicity Enhancement: EZH2 inhibition can increase tumor visibility to the immune system, enhancing the efficacy of immunotherapies by promoting T cell infiltration and activation [27][55] 9. Clinical Trials: Multiple clinical trials are investigating the combination of EZH2 inhibitors with immune checkpoint blockade therapies, indicating a strategic shift towards immunoepigenetic combinations [30][57] Other Important but Possibly Overlooked Content 1. Assay Development Support: Volition offers support for customizing assays tailored to specific drug programs and matrices, indicating a collaborative approach with pharmaceutical partners [54] 2. Toxicity Detection: The H3.1 nuclear assay can serve as an early indicator of systemic cell death, providing a sensitive method for detecting toxicity during drug development [42] 3. Logistical Considerations: Proper sample collection and processing are crucial for assay accuracy, with specific recommendations for handling plasma samples [48][58] 4. Specificity of Assays: The assays are designed to specifically detect intact circulating nucleosomes without cross-reactivity to other histone modifications [46][53] This summary encapsulates the key insights from the webinar, highlighting the advancements in epigenetic assays and their implications for cancer diagnostics and treatment.